Clinical Trials
33 trialsPET [89Zr]DFO-starPEG in Solid Tumors
University of California, San Francisco
Phase I Study in Advanced Malignancies With 5-ALA
Fox Chase Cancer Center
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
Sichuan University
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors
Children's National Research Institute
Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors
M.D. Anderson Cancer Center
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Georgetown University
Clinical Trial of WBC100 on Advanced Solid Tumor
Zhejiang University
Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HCW9218 in Select Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Technetium [99mTc]-H7ND in Patients With Gastrointestinal Malignancies and Healthy Volunteers
Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor
Chinese PLA General Hospital
Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
University of Chicago
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
Fudan University
A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors
China Medical University, China
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
Peking University
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Medical College of Wisconsin
Trial of Mistletoe Extract in Patients With Advanced Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Phase I Study of IBI325 in Patients With Advanced Solid Tumor
Shandong Cancer Hospital and Institute
A Clinical Study of Intratumoral Administration of RT-01 in Patients With Advanced Solid Tumors
Wuxi People's Hospital
Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors
University of Kentucky
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors
Dana-Farber Cancer Institute
A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
VITAC
Children's Hospital Medical Center, Cincinnati
UVA-AM-001
University of Virginia
Safety of the Combination of SH003 and Docetaxel in Patients With Solid Cancer
Kyunghee University Medical Center
Study of Regorafenib and Sildenafil for Advanced Solid Tumors
Virginia Commonwealth University
Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors
Peking University
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies
Dana-Farber Cancer Institute
Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine
ASLAN Pharmaceuticals
Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+
University of California, San Francisco
Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.
Aichi Medical University
Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies
Dana-Farber Cancer Institute